Advertisement

Ads Placeholder
Loading...

Amundi Index MSCI Pacific ex Japan SRI - UCITS ETF DR - EUR (C)

CP9.PAEURONEXT
Financial Services
Asset Management
645.30
0.60(0.09%)
U.S. Market opens in 18h 37m

Amundi Index MSCI Pacific ex Japan SRI - UCITS ETF DR - EUR (C) Fundamental Analysis

Amundi Index MSCI Pacific ex Japan SRI - UCITS ETF DR - EUR (C) (CP9.PA) shows weak financial fundamentals with a PE ratio of 21.96, profit margin of 0.00%, and ROE of 0.00%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

ROE0.00%
Operating Margin0.00%
Current Ratio0.00
We analyze CP9.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 25.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
25.0/100

We analyze CP9.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

CP9.PA struggles to generate sufficient returns from assets.

ROA > 10%
0.00%

Valuation Score

Moderate

CP9.PA shows balanced valuation metrics.

PE < 25
21.96
PEG Ratio < 2
N/A

Growth Score

Moderate

CP9.PA shows steady but slowing expansion.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

CP9.PA shows balanced financial health with some risks.

Debt/Equity < 1
0.00
Current Ratio > 1
0.00

Profitability Score

Weak

CP9.PA struggles to sustain strong margins.

ROE > 15%
0.00%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is CP9.PA Expensive or Cheap?

P/E Ratio

CP9.PA trades at 21.96 times earnings. This indicates a fair valuation.

21.96

Debt/Equity

Amundi Index MSCI Pacific ex Japan SRI - UCITS ETF DR - EUR (C) has a debt-to-equity ratio of 0.00, indicating its leverage.

0.00

How Well Does CP9.PA Make Money?

Net Profit Margin

For every $100 in sales, Amundi Index MSCI Pacific ex Japan SRI - UCITS ETF DR - EUR (C) keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $0.00 in profit for every $100 of shareholder equity.

0.00%

ROA

Amundi Index MSCI Pacific ex Japan SRI - UCITS ETF DR - EUR (C) generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.

0.00%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.00

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.00

vs 25 benchmark

ROA

Return on assets percentage

0.00

vs 25 benchmark

ROCE

Return on capital employed

0.00

vs 25 benchmark

How CP9.PA Stacks Against Its Sector Peers

MetricCP9.PA ValueSector AveragePerformance
P/E RatioN/A18.66 N/A
ROE0.00%806.00% Weak
Net Margin0.00%-451.00% (disorted) Weak
Debt/Equity0.001.00 Strong (Low Leverage)
Current Ratio0.00662.02 Weak Liquidity
ROA0.00%-24409.00% (disorted) Weak

CP9.PA outperforms its industry in 1 out of 5 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Amundi Index MSCI Pacific ex Japan SRI - UCITS ETF DR - EUR (C)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Value, Dividend, Cyclical

EPS CAGR

N/A

Industry Style: Value, Dividend, Cyclical

FCF CAGR

N/A

Industry Style: Value, Dividend, Cyclical

Fundamental Analysis FAQ